Contrave(R), a weight loss drug being developed by Orexigen(R) Therapeutics, Inc., was recommended by an expert panel of the FDA last week by a vote of 13-7. The vote surprised many who were expecting another defeat like those of lorcaserin and Qnesa earlier in the year.
There are questions about a possible link to cardiovascular issues, but the panel voted 11-8 to recommend that a study could be done post-approval, which could lead the way to FDA approval of
Contrave(R) on January 31, 2011.
Orexigen(R) is also developing another weight loss product,
Empatic(R), which may gain some attention and momentum from Contrave(R)'s approval.
Orexigen(R)'s stock zoomed from about $4.75 to more than $12.25 in after hous trading on the evening of the panel's decision, after trading had been halted for the day. On Wednesday, it floated back down to the $8-9 range where it has stayed, closing Friday at $8.43. With th possibility of approval in the fairly near future, the stock could see some interesting moves in the weeks ahead. For purposes of disclosure, I do not own any Orexigen(R) stock at the moment, though I could in the future.
Technorati Tags:
Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing WeightEmpaticQnesalorcaserinLabels: bupropion, contrave, diet pill, empatic, food and drug administration, lorcaserin, losing weight, naltrexone, qnexa, weight loss, weight loss pills